Recently Added |View More
News
Working at Roswell Park will afford you incredible opportunities to work alongside some of the nation’s foremost clinicians and researchers to broaden your career experiences and be part of a team that eases the burden of cancer.
News
Roswell Park Researchers to Discuss Recent Discoveries and Critical Issues in Oncology at AACR 2025
Researchers from Roswell Park Comprehensive Cancer Center will report their latest findings to colleagues from around the world at the 2025 annual meeting of the American Association for Cancer Research (AACR) in Chicago, Illinois, April 25-30.
News
Tumor-Infiltrating Lymphocyte Therapy Tackles Treatment Blind Spot in Advanced Melanoma
Advanced melanoma is an aggressive disease that carried a very poor prognosis until the emergence of checkpoint inhibitors approximately 15 years ago, which gave us the ability to exploit the immunogenic nature of melanoma and improve survival significantly.
Video
Meet the Team: Cerrene Giordano, MD
Cerrene Giordano, MD, believes the future of dermatology involves embracing what artificial intelligence can do to help treat patients with skin cancer.
News
Can NST-628 Fill the Treatment Void For Advanced Tumors with RAS or RAF Mutations?
A phase 1 clinical trial underway at Roswell Park Comprehensive Cancer Center will evaluate the potential of a “molecular glue” to treat MAPK pathway-mutated advanced solid tumors in patients who have exhausted standard treatment options.
News
Congressman Kennedy Announces Over $7.7 Million for State-of-the-Art Biobank at Roswell Park
Congressman Kennedy announced $7,731,872 in funding for the Roswell Park Comprehensive Cancer Center to renovate its newly integrated biobank, the Roswell Park Biorepository, made possible through the Office of the Director of the National ...
News
Roswell Park Earns ‘Exceptional’ Rating from National Cancer Institute With Best-Ever Core Grant
Region’s only Comprehensive Cancer Center earns maximum rating, marking five decades of consecutive NCI support.
Video
A Comprehensive Overview of Tumor-Infiltrating Lymphocyte (TIL) Therapy for Metastatic Melanoma
Tuesday, April 9, 2024 5:30 - 6:30 PM EDT - On the heels of the FDA’s recent approval of AMTAGVI (lifileucel) for unrescectable or metastatic melanoma, join Roswell Park subject matter experts for a comprehensive provider education event.
News
Clinical Trial Evaluates Smaller Surgical Margins for Stage 2 Melanoma Patients
Although most primary cutaneous melanomas are treated with surgical excision alone, current international guidelines vary on the optimal size for the surgical margins, which can range from 1 to 3 cm. based on Breslow thickness.
This site is intended for healthcare professionals
Click your preferred app store below to download our free mobile app — exclusively for physicians and physician offices — for direct access to a complete, up-to-date directory of Roswell Park physicians wherever you go. Email or call to refer a patient or ask a question with a click of a button.
BROADCASTMED